Background: Permanent colostomy after colorectal cancer surgery constitutes a major life change that may influence patients’ physical, psychological, and social well-being. This study aimed to evaluate these outcomes in patients with a permanent colostomy and to explore differences according to age, gender, and place of residence. Material and methods: The study included 150 adult patients with a permanent colostomy following colorectal cancer treatment. Participants were recruited during oncological follow-up visits in Poland. Quality of life was measured by the World Health Organization Quality of Life Questionnaire – Brief Version (WHOQoL-BREF), illness acceptance using the Acceptance of Illness Scale (AIS), and psychosocial functioning using an author-designed questionnaire. Sociodemographic variables included age, gender, and place of residence. Statistical analyses were performed using independent-sample t-tests and analysis of variance with a significance level of p<0.05. Results: Older participants demonstrated significantly higher quality of life, greater illness acceptance, and better psychosocial functioning than younger patients. Men reported higher quality of life and illness acceptance than women, while psychosocial functioning did not differ significantly by gender. Urban residents achieved significantly higher scores across all assessed domains compared with rural residents. Conclusions: Sociodemographic factors significantly influence adaptation to life with a permanent colostomy. Younger patients, women, and individuals living in rural areas may require additional psychosocial support and targeted interventions.
17 February 2026 in Health Problems of Civilization
Background: Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). It is also recommended as part of the therapeutic strategy for individuals with metabolic syndrome or obesity. This study aimed to evaluate the effects of semaglutide administration on body weight reduction, eating behaviors, energy intake, and appetite control in women with diagnosed obesity and insulin resistance. Material and methods: The study included 104 women diagnosed with obesity and insulin resistance who tolerated semaglutide therapy without adverse effects. Results: Participants using semaglutide demonstrated a mean decrease in daily energy intake of 103 kcal (p=0.034; d=-0.21) compared with baseline. A significant reduction in body weight (mean -2.85 kg) was observed, along with decreases in body fat content, Body Mass Index (BMI), and waist-to-hip ratio (WHR). Conclusions: Semaglutide use was associated with appetite suppression, reduced snacking frequency, and a subsequent decrease in body weight and body fat percentage, indicating its beneficial role in weight management among women with obesity and insulin resistance.